Lithium shows no benefit to MND patients
(Medical Xpress)—Results from a clinical trial into amyotrophic lateral sclerosis (ALS), led by King's College London's Institute of Psychiatry show that lithium carbonate is ineffective at treating the disease.
ALS is a type of motor neuron disease (MND). It is a neurodegenerative disease in which motor neurons in the brain and spinal cord degenerate, resulting in progressive paralysis ultimately leading to dependence on mechanical ventilator support or death, usually within 3 years. A drug called riluzole is known to improve survival in patients with ALS, but the effect is moderate and there remains a pressing need for more effective treatments.
The trial, known as the 'LiCALS trial' involved 214 patients with amyotrophic lateral sclerosis (ALS – a type of MND) who were currently taking riluzole. Patients were randomly allocated daily doses of oral lithium (107 patients), or a placebo (107 patients) and followed for 18 months.
The findings, published recently in the The Lancet Neurology, report that while lithium was safe, there was no significant increase in survival rates for patients prescribed lithium, compared to the placebo.
Previous research had found that lithium had neuroprotective effects in cells and animal models of neurodegeneration.
Professor Ammar Al-Chalabi, chief investigator of the trial from the Department of Clinical Neuroscience at King's Institute of Psychiatry, says: "A previous small study showed that lithium might slow down ALS and improve survival rates, but the result was not certain. What was needed was a definitive trial to show whether or not this was an effective treatment for patients with ALS.
"Although the results are disappointing, the trial has allowed the development of a trials network of ten centres in the UK, which will be of great benefit for rapidly testing future therapies. We are most grateful to the patients who took part in the trial and not only helped answer the question of whether lithium could treat ALS, but also helped in establishing a trials network. We will continue our search for novel treatments for this devastating disease."
Funded by the Motor Neurone Disease Association (MNDA), the trial was coordinated by the National Institute for Health Research (NIHR) DeNDRoN (Dementias and Neurodegenerative Diseases Network).
Dr Brian Dickie, Director of Research Development at the MND Association says: "As many people will know, when lithium was first proposed as having benefit in MND, a couple of small, short-term trials were performed to establish whether the drug had a large and rapid effect on physical changes in disease progression. This trial, by contrast, was developed to ask whether the drug had a more subtle benefit over a longer time course, as is the case with riluzole, using survival times as the primary measure. The only way to answer this question was by performing larger, lengthier and more comprehensive studies. While the result is deeply disappointing, we now have a clear answer."
More information: Al-Chalabi, A. et al. 'Lithium in patients with amyotrophic lateral sclerosis (LiCALS): a phase 3 multicentre, randomised, double-blind, placebo-controlled trial' The Lancet Neurology. doi:10.1016/S1474-4422(13)70037-1
Journal reference: Lancet Neurology
Provided by King's College London
- Experts: Lithium doesn't slow Lou Gehrig's disease Apr 06, 2010 | not rated yet | 0
- Novel ALS drug slows symptom progression, reduces mortality in phase II trial Nov 20, 2011 | not rated yet | 0
- Lithium shows no benefit for people with ALS Aug 11, 2010 | not rated yet | 0
- New ALS drug slips through telling 'phase II' clinical trials Jan 04, 2010 | not rated yet | 0
- Finger length clue to motor neuron disease May 11, 2011 | not rated yet | 0
- Motion perception revisited: High Phi effect challenges established motion perception assumptions Apr 23, 2013 | 3 / 5 (2) | 2
- Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update) Apr 02, 2013 | 4.5 / 5 (11) | 5
- The visual system as economist: Neural resource allocation in visual adaptation Mar 30, 2013 | 5 / 5 (2) | 9
- Separate lives: Neuronal and organismal lifespans decoupled Mar 27, 2013 | 4.9 / 5 (8) | 0
- Sizing things up: The evolutionary neurobiology of scale invariance Feb 28, 2013 | 4.8 / 5 (10) | 14
If you became brain-dead, would you want them to pull the plug?
16 hours ago I'd want the rest of me to stay alive. Sure it's a lousy way to live but it beats being all-the-way dead. Maybe if I make it 20 years they'll...
MRI bill question
May 15, 2013 Dear PFers, The hospital gave us a $12k bill for one MRI (head with contrast). The people I talked to at the hospital tell me that they do not...
Ratio of Hydrogen of Oxygen in Dessicated Animal Protein
May 13, 2013 As an experiment, for the past few months I've been consuming at least one portion of Jell-O or unflavored Knox gelatin per day. I'm 64, in very...
Alcohol and acetaminophen
May 13, 2013 Edit: sorry for the typo in the title , can't edit I looked around on google quite a bit and it's very hard to find precise information on the...
Marie Curie's leukemia
May 13, 2013 Does anyone know what might be the cause of Marie Curie's cancer
Genetic variations within and between populations
May 12, 2013 This paper (http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1893020/) asserts these two different conclusions: ---Quote--- Thus the answer to the...
- More from Physics Forums - Medical Sciences
More news stories
For combat veterans suffering from post-traumatic stress disorder, 'fear circuitry' in the brain never rests
Chronic trauma can inflict lasting damage to brain regions associated with fear and anxiety. Previous imaging studies of people with post-traumatic stress disorder, or PTSD, have shown that these brain regions can over-or ...
Neuroscience 1 hour ago | not rated yet | 0 |
The neural machinery underlying our olfactory sense continues to be an enigma for neuroscience. A recent review in Neuron seeks to expand traditional ideas about how neurons in the olfactory bulb might encode information about ...
Neuroscience 12 hours ago | not rated yet | 0 |
(Medical Xpress)—What if the quality of your work depends more on your focus on the piano keys or canvas or laptop than your musical or painting or computing skills? If target users can be convinced, they ...
Neuroscience 13 hours ago | 3.7 / 5 (3) | 0 |
Neurological disorders can have a devastating impact on the lives of sufferers and their families.
Neuroscience 18 hours ago | 5 / 5 (1) | 0 |
If you're a left-brain thinker, chances are you use your right hand to hold your cell phone up to your right ear, according to a newly published study from Henry Ford Hospital in Detroit.
Neuroscience May 16, 2013 | 2 / 5 (2) | 0 |
Big names in medicine are set to give an upbeat assessment of the war on AIDS on Tuesday, 30 years after French researchers identified the virus that causes the disease.
40 minutes ago | not rated yet | 0
(AP)—A woman who lost both hands, her left leg and right foot after contracting a flesh-eating disease has been fitted with prosthetic hands.
1 hour ago | not rated yet | 0
In 2008 researchers from the University of Southern Denmark showed that the drug thioridazine, which has previously been used to treat schizophrenia, is also a powerful weapon against antibiotic-resistant bacteria such as ...
10 hours ago | 3.7 / 5 (3) | 0 |
(Medical Xpress)—Working with lab mice models of multiple sclerosis (MS), UC Davis scientists have detected a novel molecular target for the design of drugs that could be safer and more effective than current FDA-approved ...
10 hours ago | 5 / 5 (2) | 0 |
In order to avoid harms associated with alcohol consumption, in 2009 the National Institute on Alcohol Abuse and Alcoholism issued guidelines that define low-risk drinking. These guidelines differ for men and women: no more ...
10 hours ago | not rated yet | 0 |
Treatment for alcohol use disorders works best if the patient actively understands and incorporates the interventions provided in the clinic. Multiple factors can influence both the type and degree of neurocognitive abnormalities ...
10 hours ago | not rated yet | 0 |